Closing the gap? China's new regulation on biomedical technologies

Area of Science:

• Biomedical technology regulation
• Cellular and molecular level governance

Background:

• China's State Council Order No. 818, effective May 1, 2026, introduces a new regulatory paradigm.
• Existing frameworks often focus on products, not interventions.

Purpose of the Study:

• To analyze the novel intervention-based regulatory framework established by China's State Council Order No. 818.
• To identify how this framework addresses regulatory gaps in advanced biomedical technologies.

Main Methods:

• Analysis of China's State Council Order No. 818.
• Comparative review of intervention-based vs. product-based regulatory approaches.
• Identification of regulatory gaps for specific technologies.

Main Results:

• The new framework is intervention-based, focusing on the act of biomedical intervention rather than the final product.
• It specifically targets regulatory gaps for cell therapies, gene therapies, and germline interventions.
• This approach offers a novel method for governing rapidly advancing biomedical technologies.

Conclusions:

• China's Order No. 818 represents a significant shift towards regulating the process of biomedical innovation.
• The intervention-based approach is poised to address challenges in regulating cutting-edge cell and gene therapies.
• This statutory framework provides a forward-looking model for biomedical technology governance.